M&A Deal Summary |
|
|---|---|
| Date | 2014-07-31 |
| Target | Rottapharm |
| Sector | Life Science |
| Buyer(s) | Meda |
| Deal Type | Add-on Acquisition |
| Deal Value | 3.1B USD |
| Advisor(s) | Studio Pavesi Gitti Verzoni (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Meda is an operator of an international specialty pharma company that is fully represented in Europe and the US through its own sales organizations in more than 50 countries. Meda’s products are sold in about 120 countries, and where it lacks a sales organization, it markets and sells its products via agents and other pharmaceutical companies. Meda has a diversified geographic footprint with approximately 62 percent of Meda's sales generated in Western Europe (the largest countries being Italy, Germany, France, and Sweden), 19 percent in Emerging Markets (driven by China, Russia, the Middle East, and Thailand) and 17 percent in the U.S. Meda has a network of seven manufacturing facilities in Europe, the U.S. and India. Meda is based in Solna, Sweden.
| DEAL STATS | # |
|---|---|
| Overall | 7 of 7 |
| Sector (Life Science) | 6 of 6 |
| Type (Add-on Acquisition) | 7 of 7 |
| Country (Italy) | 1 of 1 |
| Year (2014) | 1 of 1 |
| Size (of disclosed) | 1 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-08-30 |
Acton Pharmaceuticals
Marlborough, Massachusetts, United States Acton Pharmaceuticals, Inc. is a US respiratory company. Its primary product is Aerospan. Aerospan is an inhaler for the treatment of asthma that contains the active substance Flunisolide. |
Buy | $135M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-09-04 |
Meda Pharmaceuticals
Somerset, New Jersey, United States Meda Pharmaceuticals, Inc. provides pharmaceutical products. |
Sell | - |
